# OnCo record nct06040541 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06040541/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06040541", "NCT06040541" ;
  schema:name "Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors"@en ;
  schema:alternateName "RMC-9805-001"@en ;
  schema:description "A phase 1 trial of zoldonrasib (RMC-9805) alone or with daraxonrasib (RMC-6236) in KRAS G12D-mutant solid tumours, including pancreatic, bowel and non-small-cell lung cancer, run by Revolution Medicines, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06040541/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06040541> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/drugs/daraxonrasib/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/> .